CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today that Kevin D. Green,
Cerus’ vice president, finance and chief finance officer, is scheduled
to present a corporate update at the Baird 2013 Health Care Conference
in New York, NY on Tuesday, September 10, 2013, at 11:25 am ET.
A live webcast of the presentation will be available from the Investor
Relations page of the Cerus web site at http://www.cerus.com/ir.
A replay will be available for approximately two weeks following the
completion of the event.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood safety. The company’s INTERCEPT Blood System has been
demonstrated to inactivate a broad range of viruses, bacteria and
parasites that may be present in donated blood, including established
threats such as hepatitis B and C, HIV, West Nile virus and bacteria, as
well as emerging pathogens such as influenza, malaria and dengue. Cerus
currently markets and sells the INTERCEPT Blood System for both
platelets and plasma in Europe, the Commonwealth of Independent States,
the Middle East and selected countries in other regions around the
world. In the United States, Cerus is seeking regulatory approval of the
INTERCEPT Blood System for plasma and platelets. The INTERCEPT red blood
cell system is in clinical development. See http://www.cerus.com
for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
Source: Cerus Corporation